Cantor Fitzgerald raised the firm’s price target on Tenet Healthcare to $104 from $94 and keeps an Overweight rating on the shares following the Q4 earnings report. The firm views 2024 guidance as conservative, with potential for upside in the hospital segment, and sees the recent pressure on Tenet and peers related to concerns of surgical demand decline from GLP-1 usage as overdone, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on THC: